The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Yuko Oku - JP Morgan Chase & Co, Research Division - Analyst
: This is Yuko, on the call for Jessica. Starting the 180 patient Phase I/II dose optimization and expansion study in non-small cell lung cancer, that
BMY will be running, can you provide an overview of that study, including the doses that you'll be evaluating in the dose optimization phase? And
then do you plan to select patients based from PD-L1 status or any other biomarkers?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: More on PIVOT-02 and the melanoma cohort. I recall at SITC that while you had not hit your median after 18 months in PFS, it looked like the
12-month PFS was probably around 53%. So that implies maybe suppression by 1 or 2 patients would throw the curve off into the lower part --
lower half of the graph. Is it safe to say that no patients have progressed since that time? And are you, in fact, following all the patients or have
some patients been lost to follow-up and they're just censored at various time points? If you could comment on any of that, it would be great.
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: Will you have -- do you think you'll be sharing overall survival data as well?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: Okay. And then JZ, regarding 358 and the presentation of the lupus -- the Phase Ib lupus data, you're presenting at 2 conferences, at EULAR and
ACR? What will be difference -- different between those 2 presentations, if any?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: Okay. And then finally, do you think 358 could treat cytokine storm associated with COVID?
Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst
: I had maybe a follow-up question on your IL-15 agonist, 255. You already talked a little bit about what you guys are looking to see in the data set
in the initial Phase I data. I'm curious that with other IL-15s entering the clinic recently with different strategies, whether you might also talk a little
bit more in-depth about how you guys designed your IL-15? And what kind of differentiators might we look for in that early data set that you guys
are hoping to have at around year-end?
| 
